Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial
暂无分享,去创建一个
E. Kauppila | H. Merisaari | H. Aronen | I. Jambor | H. Minn | T. Noponen | S. Kajander | J. Kemppainen | J. Saunavaara | M. Seppänen | R. Huovinen | Anna Kuisma | Susan Ramadan | M. Sandell | Joakim Auren